News

Phase 2b Trial of MS1819, Yeast-based EPI for CF, Fully Enrolled

AzurRx BioPharma announced that its Phase 2b trial evaluating the safety and efficacy of MS1819 in treating exocrine pancreatic insufficiency (EPI) in cystic fibrosis (CF) patients is fully enrolled. Thirty adults with CF are taking part in the OPTION 2 study (NCT04375878) comparing MS1819 with the current standard…

CF Foundation’s Impact Grant Program Benefits Communities

One need look no further than the name of the Cystic Fibrosis Foundation‘s Impact Grant program to figure out what it does — helping those affected by cystic fibrosis (CF) serve their disease community in creative ways that matter. The CF Foundation is currently accepting applications for the 2021 award…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.